Get the Stockscreener App
147.51
0.70%
0.83
Insmed Inc stock is traded at $147.51, with a volume of 1.07M.
It is up +0.70% in the last 24 hours and up +34.83% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$146.68
Open:
$146.88
24h Volume:
1.07M
Relative Volume:
0.28
Market Cap:
$31.18B
Revenue:
$398.11M
Net Income/Loss:
$-1.03B
P/E Ratio:
-25.92
EPS:
-5.69
Net Cash Flow:
$-868.57M
1W Performance:
+1.65%
1M Performance:
+34.83%
6M Performance:
+97.23%
1Y Performance:
+105.66%
1-Day Range:
$145.25
$149.08
1-Week Range:
$140.33
$149.08
52-Week Range:
$60.40
$149.08
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
147.51 | 31.00B | 398.11M | -1.03B | -868.57M | -5.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.94 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.62 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.01 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
766.33 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Short Interest Drops in Insmed Incorporated After RallyEarnings Risk Report & Breakout Confirmation Alerts - beatles.ru
DPP1 Inhibitor Market Set to Reach New Heights in the Coming Decade | DelveInsight - GlobeNewswire Inc.
Insmed stock hits 52-week high at 146.91 USD - Investing.com
Should I buy Insmed Incorporated stock now2025 Geopolitical Influence & Daily Momentum Trading Reports - beatles.ru
A | Price Reversal in Insmed Incorporated? Traders Watch CloselyBreakout Watch & Consistent Growth Equity Picks - beatles.ru
Chart based exit strategy for Insmed IncorporatedWeekly Trade Review & Long-Term Safe Investment Plans - Newser
Should you wait for a breakout in Insmed IncorporatedEarnings Trend Report & Real-Time Buy Signal Alerts - Newser
Live market analysis of Insmed IncorporatedRate Hike & Technical Confirmation Trade Alerts - Newser
Will Insmed Incorporated benefit from rate cutsJuly 2025 Action & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
What the charts say about Insmed Incorporated today2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
Insmed at Wells Fargo Conference: Strategic Growth and Future Plans By Investing.com - Investing.com Canada
Insmed at Wells Fargo Conference: Strategic Growth and Future Plans - Investing.com
Significant Outflows Detected in Biotech ETFs: XBI, ALNY, INSM, HALO - AInvest
Can Insmed Incorporated lead its sector in growthWeekly Stock Report & Weekly Consistent Profit Watchlists - خودرو بانک
Custom watchlist performance reports with Insmed IncorporatedJuly 2025 Momentum & Safe Investment Capital Preservation Plans - Newser
Transcript : Insmed Incorporated Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-05-2025 08 - MarketScreener
Key resistance and support levels for Insmed IncorporatedQuarterly Market Summary & Technical Pattern Recognition Alerts - Newser
Combining price and volume data for Insmed IncorporatedMarket Movement Recap & AI Driven Price Forecasts - Newser
Will earnings trigger a reversal in Insmed IncorporatedJuly 2025 Movers & Weekly High Return Opportunities - Newser
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - MarketScreener
Insmed CMO Flammer sells $26.9m in stock after option exercise - Investing.com Australia
Insmed's Tumultuous Day Insider Sales and 20 Volume Drop Sink Stock to 372nd Market Rank - AInvest
Has Insmed Incorporated found a price floorEarnings Overview Summary & Community Consensus Picks - Newser
Insmed CLO Smith sells $3.49m in shares - Investing.com
Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri - Yahoo Finance
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - MSN
Developing predictive dashboards with Insmed Incorporated data2025 Institutional Moves & Reliable Breakout Forecasts - Newser
Is Insmed Incorporated forming a reversal patternTrade Analysis Report & Daily Volume Surge Signals - Newser
Will Insmed Incorporated stock hit new highs in YEARTreasury Yields & Detailed Earnings Play Alerts - خودرو بانک
Analyzing net buyer seller activity in Insmed IncorporatedJuly 2025 Review & Target Return Focused Picks - Newser
Sentiment analysis tools applied to Insmed IncorporatedJuly 2025 Sector Moves & Weekly Market Pulse Updates - Newser
Insmed Shares Slide 1.24% Amid 48.65% Volume Drop to 286th Rank as Wells Fargo Raises Target to $171 - AInvest
Trend Review: Will Insmed Incorporated benefit from rate cutsRecession Risk & Smart Money Movement Alerts - خودرو بانک
Mizuho Securities Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
Analyzing drawdowns of Insmed Incorporated with statistical tools2025 Market Sentiment & Free Real-Time Market Sentiment Alerts - Newser
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $142 to $171 - 富途牛牛
Signal strength of Insmed Incorporated stock in tech scannersGlobal Markets & Smart Money Movement Tracker - Newser
Is Insmed Incorporated still worth holding after the dip2025 Market Sentiment & Real-Time Stock Price Movement Reports - Newser
Insmed (INSM) Soars 6.76% After FDA Approves Brinsupri for Non-CF Bronchiectasis - AInvest
Will Insmed Incorporated outperform small cap indexesWeekly Trade Review & AI Forecast for Swing Trade Picks - خودرو بانک
Insmed (INSM) Surges 6.76% on Bullish Technical Signals Faces Key Resistance at $140 - AInvest
Insmed Stock Surges 13.23% to $145.30 Amid Strong Bullish Momentum - AInvest
Is Insmed Incorporated stock forming a cup and handleMarket Sentiment Summary & Entry Point Confirmation Alerts - خودرو بانک
Why United Just Catapulted 39%, Pulling Two Rivals With It - Investor's Business Daily
Brinsupri Boost: Is Insmed Stock Undervalued? - StocksToTrade
What high frequency data says about Insmed Incorporated2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
Insmed Stock Soars: Buy or Hold Timeout? - timothysykes.com
Insmed Stock Jumps: What’s Driving Change? - StocksToTrade
What analysts say about Insmed Incorporated stockEarnings Risk Report & Growth Focused Stock Pick Reports - khodrobank.com
Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development - TipRanks
Insmed Surges 5.9% on Intraday Rally: What’s Fueling the Momentum? - AInvest
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Michael Alexander | Chief Legal Officer |
Sep 02 '25 |
Sale |
143.89 |
24,272 |
3,492,378 |
54,902 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
23.40 |
186,648 |
4,366,788 |
269,759 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 02 '25 |
Sale |
144.34 |
186,648 |
26,941,272 |
83,111 |
0.82%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):